S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,253.88 (+0.10%)
DOW   39,767.51 (+0.02%)
QQQ   444.80 (+-0.01%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
NASDAQ:ATNF

180 Life Sciences (ATNF) Stock Price, News & Analysis

$2.04
+0.04 (+1.74%)
(As of 10:28 AM ET)
Today's Range
$1.95
$2.12
50-Day Range
$1.98
$4.34
52-Week Range
$1.80
$51.30
Volume
33,436 shs
Average Volume
105,257 shs
Market Capitalization
$797,550.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ATNF stock logo

About 180 Life Sciences Stock (NASDAQ:ATNF)

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

ATNF Stock Price History

ATNF Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
180 Life Sciences Announces 1-For 19 Reverse Stock Split - Quick Facts
180 Life Sciences Corp.
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
180 Life Sciences Corp. Common Stock (ATNF)
Why Is 180 Life Sciences (ATNF) Stock Up 30% Today?
See More Headlines
Receive ATNF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 180 Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/27/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ATNF
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-38,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$67.00 per share
Book Value
$57.56 per share

Miscellaneous

Free Float
377,000
Market Cap
$783,900.00
Optionable
No Data
Beta
0.47
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Sir Marc Feldmann Ph.D. (Age 78)
    Co-Founder & Executive Co-Chairman
    Comp: $232.97k
  • Dr. Lawrence Steinman BA (Age 76)
    M.D., Ph.D., Co-Founder & Executive Co-Chairman
    Comp: $168.75k
  • Dr. James N. Woody M.D. (Age 82)
    Ph.D., CEO & Director
    Comp: $617.77k
  • Mr. Ozan Pamir C.F.A. (Age 32)
    CFO & Secretary
    Comp: $410.24k
  • Dr. Jonathan B. Rothbard Ph.D. (Age 71)
    Chief Scientific Officer
    Comp: $260.34k
  • Prof. Jagdeep Nanchahal
    Co-Founder & Chairman of Clinical Advisory Board
  • Mr. Jason Assad
    Director of IR

ATNF Stock Analysis - Frequently Asked Questions

How have ATNF shares performed in 2024?

180 Life Sciences' stock was trading at $4.0565 at the start of the year. Since then, ATNF shares have decreased by 51.9% and is now trading at $1.9510.
View the best growth stocks for 2024 here
.

Are investors shorting 180 Life Sciences?

180 Life Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 61,800 shares, an increase of 309.3% from the February 29th total of 15,100 shares. Based on an average trading volume of 97,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 12.2% of the company's stock are short sold.
View 180 Life Sciences' Short Interest
.

When is 180 Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ATNF earnings forecast
.

When did 180 Life Sciences' stock split?

180 Life Sciences shares reverse split on the morning of Wednesday, February 28th 2024. The 1-19 reverse split was announced on Wednesday, February 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are 180 Life Sciences' major shareholders?

180 Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James N Woody, Jr Donald A Mcgovern, Ozan Pamir, Pamela G Marrone and Quan Anh Vu.
View institutional ownership trends
.

How do I buy shares of 180 Life Sciences?

Shares of ATNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATNF) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners